Results 101 to 110 of about 8,864 (209)

PCN132 Cost-Effectiveness Analysis of RE-Treatment with 177lu-Dotatate Versus NO RE-Treatment with 177lu-Dotatate in Patients with Progressive Midgut Neuroendocrine Tumors [PDF]

Value in Health, 2020
O. Leeuwenkamp, R. Mahon, M.K. Singh, A. Khare   +3 more
openaire   +1 more source

NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

, 2019
With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing.
Gardner, Linda, Strosberg, Jonathan R, Lindsay, Sheila, Metz, David C, Colucci, Karen, Hope, Thomas A, Graham, William S, Abbott, Amanda, Pryma, Daniel A, Bushnell, David L, Stabin, Michael G   +10 more
core   +1 more source

Efficacy of Intra-arterial [177Lu]Lu-DOTATATE monotherapy for treatment-refractory meningioma

Purpose: For meningiomas that are refractory after local treatments, there are no systemic evidence-based therapeutic options to date. In recent years, somatostatin-targeted radionuclide therapy has emerged as a promising new treatment modality.
El Ghalbouni, A., MS Radiologie, Brain, Braat, A. J.A.T., Patt, M., van der Schaaf, I. C., Arts-assistenten Nucleaire Geneesk., Maurer, C. J., Onderzoek Beeld, Neurologen, Amerein, A., Snijders, T. J., Tolboom, N., Circulatory Health, Lapa, C., Cancer   +15 more
core  

Semiquantitative SSTR PET metrics show molecular-morphologic discordance after 177Lu-DOTATATE in gastroenteropancreatic neuroendocrine neoplasms: an exploratory paired target-lesion analysis. [PDF]

Ann Nucl Med
Chiaravalloti A, Egidi M, D'Agostini A, Filippi L, Triumbari EKA, Bagni O, Schillaci O.   +6 more
europepmc   +1 more source

Lung Metastases from Meningioma Diagnosed on Whole Body 68Ga-DOTATOC PET/CT and Successfully Targeted With 177Lu-DOTATATE. [PDF]

Clin Nucl Med
Bekkhoucha A, Agrigoroaie L, Deandreis D, Guyon D, Chehade F.   +4 more
europepmc   +1 more source

Validation of Simplified Renal Dosimetry Protocols for ¹⁷⁷Lu-DOTATATE Therapy Using the IDAC-dose Software. [PDF]

Mol Imaging Radionucl Ther
Yokouchi A, Shibutani T, Konishi T, Yoneyama H, Ichikawa H, Wakabayashi H.   +5 more
europepmc   +1 more source

Posology for 177Lu-DOTATATE Therapy in Neuroendocrine Tumor: Effectiveness of Dose Reduction and Cycle Delay for Improving Therapy Tolerability. [PDF]

Clin Nucl Med
Wang IE, Patterson J, Akhavanallaf A, Lu Z, Viglianti BL, Roseland M, Muhleman M, Frey KA, Scott PJH, Dewaraja YK, Wong KK.   +10 more
europepmc   +1 more source

Optimization of Gravity Infusion Protocols for ¹⁷⁷Lu-DOTATATE Administration in Peptide Receptor Radionuclide Therapy. [PDF]

Pharmaceutics
Grasso S, Varallo A, Gaudieri V, Klain M, Pastore R, Arena S, Oliviero C, Buono M, Manzi D, Schiano R, Nappi C, Totaro P, Bonifacio RR, Cuocolo A, Clemente S.   +14 more
europepmc   +1 more source

Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model. [PDF]

Mol Cancer Ther, 2023
Sharma R, Earla B, Baidoo KE, Zeiger MA, Madigan JP, Escorcia FE, Sadowski SM.   +6 more
europepmc   +1 more source

177Hf as a Competitor in the Synthesis of 177Lu-DOTAtate

Journal of Chemistry and Chemical Engineering, 2016
openaire   +1 more source